Efficacy of Sildenafil in Preterm Preeclampsia

• Status: Withdrawn
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

Randomized controlled trial to assess efficacy of Sildenafil in addition to expectant management for the treatment of preterm preeclampsia

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

1. Hospitalized patients of gestational age of ≥24 0/7 weeks to ≤32 0/7 weeks.

2. Dating of pregnancy by ultrasound < or equal to 22 weeks or IVF conception

3. Diagnosis of Preterm Preeclampsia or Superimposed Preeclampsia

Exclusion Criteria:

1. Need for immediate delivery of the fetus

2. Known lethal anomaly

3. Pre-existing renal disease

4. Hypersensitivity to sildenafil

5. Pre-gestational diabetes, class C (onset prior to 10-19 or duration 10-19 yrs

6. Active peptic ulcer disease

7. Undergoing nitrate therapy